A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide
Inclusion Criteria:
- Written informed consent
- Histological verification of primary GBM
- Recurrence or progression after standard treatment (debulking surgery of possible,
radiotherapy and temozolamide within last six months)
- Evidence of measurable recurrent progressive primary GBM (CT/MRI scan)
- PS 0-2 (ECOG scale)
- Age > 18
- Life expectancy > 3 month
- Normal organ function:
- Platelets > 125 x 109/l
- Hemoglobin >6,2 mmol/l
- Leukocytes > 3 x 109/l
- ACN> 1,5 x 109/l
- ASAT and/or ALAT < 3 x upper normal limit
- Bilirubin < 1,5 x upper normal limit
- Creatinine clearance > 45 ml/min
- Creatinine < 1,5 x upper normal limit
- APTT < normal limit
- INR < normal limit
- Cholesterol < 7 mmol/l
- Fertile females must use oral contraceptive, IUD (intrauterine device) or
preservatives. Fertile males must use preservatives.
Exclusion criteria:
- Radiotherapy or chemotherapy within the last 4 weeks.
- Co-medication that may interfere with study results; e.g. immunosuppressive agents
other than corticosteroids
- Prior EGFR- or VEGFR- based therapy.
- Any condition (medical, social, psychological), which would prevent adequate
information and follow-up
- Any other active malignancy or previous malignancies within the last 5 years, except,
adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in
situ.
- No hypercholesterolemia or hypertriglyceridemia (despite lipid-lowering therapy).
- Any significant cardiac disease (New York Heart Association Class II or greater),
arrhythmia, congestive heart failure, acute myocardial infarction within 6 months or
unstable angina pectoris.
- Clinically significant peripheral vascular disease
- Evidence of bleeding diathesis, coagulapathy or taking ASA, NSAIDs or clopidogrel
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to day 0, anticipation of need for major surgical procedure during the curse of
the study
- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
prior to day 0
- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 6 month prior to day 0
- History of known HIV, Hepatitis B and Hepatitis C negative
- Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound,
ulcer or bone fracture
- Pregnancy or breast feeding
- Requires therapeutic anti-coagulation
- Blood pressure > 150/100 mmHG
- Grade 2 or greater proteinuria